Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection

Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezloto...

Descripción completa

Detalles Bibliográficos
Autores principales: Escudero-Sánchez, Rosa, Ruiz-Ruigómez, María, Fernández-Fradejas, Jorge, García Fernández, Sergio, Olmedo Samperio, María, Cano Yuste, Angela, Valencia Alijo, Angela, Díaz-Pollán, Beatriz, Rodríguez Hernández, María Jesús, Merino De Lucas, Esperanza, Martín Segarra, Oriol, Sáez Bejar, Carmen, Armiñanzas Castillo, Carlos, Gutiérrez-Gutiérrez, Belén, Rodríguez-Pardo, Dolors, Ramos-Martínez, Antonio, Torre-Cisneros, Julián, López-Medrano, Francisco, Cobo Reinoso, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792623/
https://www.ncbi.nlm.nih.gov/pubmed/33374989
http://dx.doi.org/10.3390/jcm10010002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792623/
https://www.ncbi.nlm.nih.gov/pubmed/33374989
http://dx.doi.org/10.3390/jcm10010002

Ejemplares similares